August 8, 2024 11:49 AM EDT
R&D

Lil­ly’s an­ti-tau pill for Alzheimer’s fails in Phase 2 study

Ryan Cross

Senior Science Correspondent

One month af­ter the long-await­ed ap­proval of its first Alzheimer’s drug, Eli Lil­ly said that an­oth­er ex­per­i­men­tal med­i­cine aimed at slow­ing de­men­tia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times